Market revenue in 2023 | USD 3.3 million |
Market revenue in 2030 | USD 4.1 million |
Growth rate | 3.2% (CAGR from 2023 to 2030) |
Largest segment | Controls |
Fastest growing segment | Calibrators |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Controls, Calibrators |
Key market players worldwide | Siemens Healthineers AG ADR, Abbott Laboratories, Bio-Rad Laboratories Inc, Danaher Corp, Roche Holding AG ADR, Sysmex Corp, QuidelOrtho Corp, Thermo Fisher Scientific Inc, BD, Merck KGaA, Qiagen NV, Hologic Inc, Bio-Techne Corp, Randox, Helena Laboratories, Seracare Life Sciences, Fortress Diagnostics, Microbiologics, TRINA BIOREACTIVES, Cone Bioproducts, Biorex Food Diagnostics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to in vitro diagnostics quality control market will help companies and investors design strategic landscapes.
Controls was the largest segment with a revenue share of 48.48% in 2023. Horizon Databook has segmented the Norway in vitro diagnostics quality control market based on controls, calibrators covering the revenue growth of each sub-segment from 2018 to 2030.
Norway has a high prevalence of chronic disorders, which propels the need for the development of novel diagnostics to meet the rising demand for diagnosis. Continuous developments by companies operating in the market are contributing to the country’s market growth.
Furthermore, government initiatives are propelling the need for advanced diagnostic solutions in the market, fueling the demand for IVD quality control in the country. In November 2022, the Norwegian Directorate of e-Health updated the National Laboratory Code (NLK) system and associated tariffs for state & private laboratories, which was implemented before January 2023.
The NLK system is designed for activity-based reimbursement for laboratory tests conducted in outpatient settings. Moreover, strategic initiatives undertaken by regional market players are anticipated to drive market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway in vitro diagnostics quality control market , including forecasts for subscribers. This country databook contains high-level insights into Norway in vitro diagnostics quality control market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account